CD4 and neoplasm: (233) tested anti-tumor effects of IL13Rα2-specific CAR T cells engineered from purified CD4+ or CD8+ TCM pools and showed superior tumor killing by CD4+ CAR-T cells, along with higher cytokine production and persistent effector function upon tumor challenge, when compared with CD8+ CAR-T cells.